APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tenosynovitis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tenosynovitis Drugs Market Outlook and Growth Opportunities 2026

2 January 2026195 pages

Choose your research edition.

Industry ResearchTenosynovitis Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Tenosynovitis Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Tenosynovitis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tenosynovitis Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Tenosynovitis Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Tenosynovitis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tenosynovitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tenosynovitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tenosynovitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tenosynovitis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tenosynovitis Drugs market include GSK, Teva, Sanofi, Merck, Eli Lilly, Pfizer, Bayer, AstraZeneca and Yunnan Baiyao, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Tenosynovitis Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tenosynovitis Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tenosynovitis Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Tenosynovitis Drugs market.

Tenosynovitis Drugs Segment by Company

GSK

Teva

Sanofi

Merck

Eli Lilly

Pfizer

Bayer

AstraZeneca

Yunnan Baiyao

Teikoku Seiyaku

Sun Flower

Mikasa Seiyaku

Grunenthal

Endo

Tenosynovitis Drugs Segment by Type

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

Antibiotics

Corticosteroids

Tenosynovitis Drugs Segment by Application

Hospitals

Drugstores

Others

Tenosynovitis Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Tenosynovitis Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Tenosynovitis Drugs key companies, revenue, market share, and recent developments.

3. To split the Tenosynovitis Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Tenosynovitis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tenosynovitis Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Tenosynovitis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tenosynovitis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tenosynovitis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tenosynovitis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tenosynovitis Drugs industry.

Chapter 3: Detailed analysis of Tenosynovitis Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Tenosynovitis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Tenosynovitis Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tenosynovitis Drugs Industry Trends Table 2. Tenosynovitis Drugs Industry Drivers Table 3. Tenosynovitis Drugs Industry Opportunities and Challenges Table 4. Tenosynovitis Drugs Industry Restraints Table 5. Global Tenosynovitis Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tenosynovitis Drugs Revenue Share by Company (2021-2026) Table 7. Global Tenosynovitis Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Tenosynovitis Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Tenosynovitis Drugs Company, Product Type & Application Table 10. Global Tenosynovitis Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Tenosynovitis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Table 15. Significant Companies of Antibiotics Table 16. Significant Companies of Corticosteroids Table 17. Global Tenosynovitis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Tenosynovitis Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Tenosynovitis Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Tenosynovitis Drugs Sales Value Share by Type (2021-2026) Table 21. Global Tenosynovitis Drugs Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospitals Table 23. Significant Companies of Drugstores Table 24. Significant Companies of Others Table 25. Global Tenosynovitis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Tenosynovitis Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Tenosynovitis Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Tenosynovitis Drugs Sales Value Share by Application (2021-2026) Table 29. Global Tenosynovitis Drugs Sales Value Share by Application (2027-2032) Table 30. Global Tenosynovitis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Tenosynovitis Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Tenosynovitis Drugs Sales Value Share by Region (2021-2026) Table 33. Global Tenosynovitis Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Tenosynovitis Drugs Sales Value Share by Region (2027-2032) Table 35. Global Tenosynovitis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Tenosynovitis Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Tenosynovitis Drugs Sales Value Market Share by Country (2021-2026) Table 38. Global Tenosynovitis Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Tenosynovitis Drugs Sales Value Market Share by Country (2027-2032) Table 40. GSK Company Information Table 41. GSK Business Overview Table 42. GSK Tenosynovitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. GSK Tenosynovitis Drugs Product Portfolio Table 44. GSK Recent Development Table 45. Teva Company Information Table 46. Teva Business Overview Table 47. Teva Tenosynovitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Teva Tenosynovitis Drugs Product Portfolio Table 49. Teva Recent Development Table 50. Sanofi Company Information Table 51. Sanofi Business Overview Table 52. Sanofi Tenosynovitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Sanofi Tenosynovitis Drugs Product Portfolio Table 54. Sanofi Recent Development Table 55. Merck Company Information Table 56. Merck Business Overview Table 57. Merck Tenosynovitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Merck Tenosynovitis Drugs Product Portfolio Table 59. Merck Recent Development Table 60. Eli Lilly Company Information Table 61. Eli Lilly Business Overview Table 62. Eli Lilly Tenosynovitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Eli Lilly Tenosynovitis Drugs Product Portfolio Table 64. Eli Lilly Recent Development Table 65. Pfizer Company Information Table 66. Pfizer Business Overview Table 67. Pfizer Tenosynovitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Pfizer Tenosynovitis Drugs Product Portfolio Table 69. Pfizer Recent Development Table 70. Bayer Company Information Table 71. Bayer Business Overview Table 72. Bayer Tenosynovitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Bayer Tenosynovitis Drugs Product Portfolio Table 74. Bayer Recent Development Table 75. AstraZeneca Company Information Table 76. AstraZeneca Business Overview Table 77. AstraZeneca Tenosynovitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. AstraZeneca Tenosynovitis Drugs Product Portfolio Table 79. AstraZeneca Recent Development Table 80. Yunnan Baiyao Company Information Table 81. Yunnan Baiyao Business Overview Table 82. Yunnan Baiyao Tenosynovitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Yunnan Baiyao Tenosynovitis Drugs Product Portfolio Table 84. Yunnan Baiyao Recent Development Table 85. Teikoku Seiyaku Company Information Table 86. Teikoku Seiyaku Business Overview Table 87. Teikoku Seiyaku Tenosynovitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Teikoku Seiyaku Tenosynovitis Drugs Product Portfolio Table 89. Teikoku Seiyaku Recent Development Table 90. Sun Flower Company Information Table 91. Sun Flower Business Overview Table 92. Sun Flower Tenosynovitis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Sun Flower Tenosynovitis Drugs Product Portfolio Table 94. Sun Flower Recent Development Table 95. Mikasa Seiyaku Company Information Table 96. Mikasa Seiyaku Business Overview Table 97. Mikasa Seiyaku Tenosynovitis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Mikasa Seiyaku Tenosynovitis Drugs Product Portfolio Table 99. Mikasa Seiyaku Recent Development Table 100. Grunenthal Company Information Table 101. Grunenthal Business Overview Table 102. Grunenthal Tenosynovitis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Grunenthal Tenosynovitis Drugs Product Portfolio Table 104. Grunenthal Recent Development Table 105. Endo Company Information Table 106. Endo Business Overview Table 107. Endo Tenosynovitis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Endo Tenosynovitis Drugs Product Portfolio Table 109. Endo Recent Development Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Tenosynovitis Drugs Product Image Figure 2. Global Tenosynovitis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tenosynovitis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Tenosynovitis Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Image Figure 8. Antibiotics Image Figure 9. Corticosteroids Image Figure 10. Global Tenosynovitis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Tenosynovitis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Tenosynovitis Drugs Sales Value Share by Type (2021-2032) Figure 13. Hospitals Image Figure 14. Drugstores Image Figure 15. Others Image Figure 16. Global Tenosynovitis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Tenosynovitis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Tenosynovitis Drugs Sales Value Share by Application (2021-2032) Figure 19. Global Tenosynovitis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Tenosynovitis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Tenosynovitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. North America Tenosynovitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Tenosynovitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Tenosynovitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Tenosynovitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Tenosynovitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Tenosynovitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. South America Tenosynovitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Tenosynovitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Tenosynovitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Tenosynovitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Antibiotics
  • Corticosteroids
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • GSK
  • Teva
  • Sanofi
  • Merck
  • Eli Lilly
  • Pfizer
  • Bayer
  • AstraZeneca
  • Yunnan Baiyao
  • Teikoku Seiyaku
  • Sun Flower
  • Mikasa Seiyaku
  • Grunenthal
  • Endo

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tenosynovitis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tenosynovitis Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Tenosynovitis Drugs Market Dynamics
  1. 2.1 Tenosynovitis Drugs Industry Trends
  2. 2.2 Tenosynovitis Drugs Industry Drivers
  3. 2.3 Tenosynovitis Drugs Industry Opportunities and Challenges
  4. 2.4 Tenosynovitis Drugs Industry Restraints
3 Tenosynovitis Drugs Market by Company
  1. 3.1 Global Tenosynovitis Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Tenosynovitis Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Tenosynovitis Drugs Company Ranking (2024-2026)
  4. 3.4 Global Tenosynovitis Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Tenosynovitis Drugs Company Product Type and Application
  6. 3.6 Global Tenosynovitis Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Tenosynovitis Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Tenosynovitis Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Tenosynovitis Drugs Market by Type
  1. 4.1 Tenosynovitis Drugs Type Introduction
  2. 4.1.1 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  3. 4.1.2 Antibiotics
  4. 4.1.3 Corticosteroids
  5. 4.2 Global Tenosynovitis Drugs Sales Value by Type
  6. 4.2.1 Global Tenosynovitis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Tenosynovitis Drugs Sales Value by Type (2021-2032)
  8. 4.2.3 Global Tenosynovitis Drugs Sales Value Share by Type (2021-2032)
5 Tenosynovitis Drugs Market by Application
  1. 5.1 Tenosynovitis Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Drugstores
  4. 5.1.3 Others
  5. 5.2 Global Tenosynovitis Drugs Sales Value by Application
  6. 5.2.1 Global Tenosynovitis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Tenosynovitis Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Tenosynovitis Drugs Sales Value Share by Application (2021-2032)
6 Tenosynovitis Drugs Regional Value Analysis
  1. 6.1 Global Tenosynovitis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tenosynovitis Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Tenosynovitis Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Tenosynovitis Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tenosynovitis Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Tenosynovitis Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Tenosynovitis Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Tenosynovitis Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Tenosynovitis Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Tenosynovitis Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Tenosynovitis Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Tenosynovitis Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Tenosynovitis Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Tenosynovitis Drugs Sales Value Share by Country, 2025 VS 2032
7 Tenosynovitis Drugs Country-level Value Analysis
  1. 7.1 Global Tenosynovitis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tenosynovitis Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Tenosynovitis Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Tenosynovitis Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Tenosynovitis Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Tenosynovitis Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Tenosynovitis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Tenosynovitis Drugs Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Tenosynovitis Drugs Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Tenosynovitis Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Tenosynovitis Drugs Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Tenosynovitis Drugs Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Tenosynovitis Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Bayer
  38. 8.7.1 Bayer Company Information
  39. 8.7.2 Bayer Business Overview
  40. 8.7.3 Bayer Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bayer Tenosynovitis Drugs Product Portfolio
  42. 8.7.5 Bayer Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Tenosynovitis Drugs Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
  49. 8.9 Yunnan Baiyao
  50. 8.9.1 Yunnan Baiyao Company Information
  51. 8.9.2 Yunnan Baiyao Business Overview
  52. 8.9.3 Yunnan Baiyao Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Yunnan Baiyao Tenosynovitis Drugs Product Portfolio
  54. 8.9.5 Yunnan Baiyao Recent Developments
  55. 8.10 Teikoku Seiyaku
  56. 8.10.1 Teikoku Seiyaku Company Information
  57. 8.10.2 Teikoku Seiyaku Business Overview
  58. 8.10.3 Teikoku Seiyaku Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teikoku Seiyaku Tenosynovitis Drugs Product Portfolio
  60. 8.10.5 Teikoku Seiyaku Recent Developments
  61. 8.11 Sun Flower
  62. 8.11.1 Sun Flower Company Information
  63. 8.11.2 Sun Flower Business Overview
  64. 8.11.3 Sun Flower Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sun Flower Tenosynovitis Drugs Product Portfolio
  66. 8.11.5 Sun Flower Recent Developments
  67. 8.12 Mikasa Seiyaku
  68. 8.12.1 Mikasa Seiyaku Company Information
  69. 8.12.2 Mikasa Seiyaku Business Overview
  70. 8.12.3 Mikasa Seiyaku Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Mikasa Seiyaku Tenosynovitis Drugs Product Portfolio
  72. 8.12.5 Mikasa Seiyaku Recent Developments
  73. 8.13 Grunenthal
  74. 8.13.1 Grunenthal Company Information
  75. 8.13.2 Grunenthal Business Overview
  76. 8.13.3 Grunenthal Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Grunenthal Tenosynovitis Drugs Product Portfolio
  78. 8.13.5 Grunenthal Recent Developments
  79. 8.14 Endo
  80. 8.14.1 Endo Company Information
  81. 8.14.2 Endo Business Overview
  82. 8.14.3 Endo Tenosynovitis Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Endo Tenosynovitis Drugs Product Portfolio
  84. 8.14.5 Endo Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst